Research on antibodies and their uses. Covers engineered antitoxin antibodies, long-lasting immunity, monoclonal therapies, and antiviral T cells.
A Tel Aviv University study proposes a novel approach to manipulate genes using a self-assembling platform that delivers nucleic acids to distinct cell subsets. The platform shows promise in treating autoimmune diseases and cancer by targeting specific cells and reducing inflammation.
Emory immunologist Max Cooper and Dr. Jacques Miller are recognized for deciphering the two types of lymphocyte lineages involved in adaptive immunity, laying the groundwork for understanding nearly all fields touched by immunology. Their discoveries have fueled advancements in anti-cancer drugs and treatments for autoimmune diseases.
Researchers at Aarhus University have found a new mechanism by which an antibody can prevent allergic reactions, including those caused by birch pollen and insect venom. The antibody interferes with the binding of IgE molecules to immune cells, thereby eliminating allergic symptoms.
A new study published in mBio found that people with higher levels of anti-HA stem antibodies have less viral shedding when they get the flu, but do not have fewer or less severe signs of illness. The study suggests that these antibody levels are not independent predictors of whether someone becomes sick or how severely.
A new assay has been developed to detect HIV antibodies in oral fluid, showing high sensitivity and specificity. This assay may enable early diagnosis of HIV infection in populations at risk, potentially improving public health efforts.
Researchers successfully developed antibodies that disabled the Plasmodium vivax malaria parasite from infecting humans by hijacking a protein crucial for iron delivery. The discovery solved a decades-long mystery and brings the world closer to a potential effective vaccine against P.vivax malaria.
Researchers found that a vaccine inducing killer T cells provides broader protection for children of vaccinated mothers. The vaccine prevents the immune system from producing antibodies specific to the virus and induces protective killer T cells that can recognize and attack the virus.
Scientists at UTHealth and UT Health San Antonio are developing an innovative antibody-based drug to stem the spread of breast cancer to bone, linked to reduced survival rates. The goal is to create a less toxic treatment and reduce deaths tied to breast cancer's spread.
Researchers developed an experimental heroin vaccine that induces antibodies blocking the drug's effects, preventing euphoria and addictive properties. The vaccine appears to dampen the impact of heroin at high doses, potentially preventing overdose. Antibodies induced by the vaccine do not cross-react with therapies for opioid misuse.
A recent study published in PLOS ONE and American Journal of Pathology suggests that Lyme bacteria can survive a 28-day course of antibiotics for months after infection. The study found living B. burgdorferi spirochetes in ticks and multiple organs of primates treated with doxycycline, as well as persistent infections in some subjects.
A study of 142 women and 12 men found an association between maternal immune response to the Y-linked protein NLGN4Y and sexual orientation in male offspring. Higher antibody concentrations were detected in mothers of homosexual sons compared to those with heterosexual sons or no sons.
Researchers say new diagnostic methods can accurately detect Lyme disease earlier, improving patient outcomes and avoiding severe long-term health problems. The improved tests are less susceptible to false-positive or false-negative results associated with current antibody-based tests.
Researchers from Helmholtz Munich used computer analysis to study IgG antibodies and reveal new steps in the glycosylation pathway. The findings confirmed predictions made by an algorithm and were replicated using genome-wide association studies and laboratory experiments.
Researchers at the German Cancer Research Center found that natural infection with malaria induces a strong immune response, producing antibodies that protect mice from infection. The study's findings will help develop more effective and specific vaccines against the disease.
Scientists have developed Trim-Away, a novel method that directly and quickly depletes proteins from any cell type. This technique utilizes a protein called Trim21 to recognize antibodies directed against specific cellular proteins, allowing researchers to study their function in natural environment.
Scientists provide detailed picture of how human antibodies bind to malaria parasite's circumsporozoite protein, a key target for vaccine development. The study could lead to enhanced efficacy and duration of protection against malaria.
A recent study by La Jolla Institute for Allergy and Immunology reveals that dengue immunity can confer protection against Zika virus. Cytotoxic T-cells have been identified as crucial in defending against both viruses, suggesting that vaccines targeting either dengue or Zika could be effective.
A new study found that a mutation in the H3N2 strain of the virus is responsible for the low efficacy of last year's influenza vaccine. The team suggests investing in new technologies to produce egg-free vaccines, while emphasizing the importance of annual flu vaccination.
Researchers at the University of Louisville discovered a new autoimmune disease that causes kidney failure, dubbed anti-brush border antibody (ABBA) disease. The disease was identified after analyzing biopsied kidney tissue from patients with acute kidney injury, and it affects the nephrons' brush borders by coating them with antibodies.
A new study in Nicaraguan children pinpoints a narrow window of antibody levels that enhances reaction to severe dengue, shedding light on the long-standing phenomenon of antibody-dependent enhancement (ADE). The findings hold important implications for vaccine development against dengue and related flaviviruses like Zika.
Researchers found that blocking IL-17A and IL-17F significantly reduces symptoms of severe allergic asthma in mice. The study suggests a new potential treatment for people with this condition, by preventing the production of pro-inflammatory molecules triggered by T-helper cells.
Scientists have discovered that weak binding between antibodies and biological gels like mucus is more effective in trapping pathogens, making it a stronger first line of defense. This finding has the potential to revolutionize the treatment and prevention of various diseases by providing new targets for engineered antibodies.
A study published in Nature Immunology has found that a specific type of immune cell, called T follicular regulatory cells, plays a crucial role in preventing autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus after viral infections. These cells prevent the generation of self-reactive antibody responses whil...
A new paper-based test developed by MIT researchers can diagnose Zika infection within 20 minutes, accurately distinguishing it from Dengue virus. The test uses antibodies specific to Zika virus's NS1 protein, avoiding false positives common with existing tests.
A newly-developed dipstick test sensitively identified Zika virus and all four dengue virus subtypes with no cross-reactivity. The test detected viral proteins at lower concentrations, making it a potential tool for diagnosing emerging pathogens.
A new study by University of Nottingham researchers found that a positive mood on the day of flu vaccination can significantly increase its protective effect. The study, which measured factors such as mood, physical activity and diet, showed that good mood was associated with higher levels of antibody after vaccination.
A new study shows an antibody that prevents dengue disease also protects mice from Zika. Administering the antibody soon after infection can protect fetuses from Zika-related birth defects.
Researchers found that a combination of two broadly-neutralizing HIV-1 antibodies protected primates against infection with a mixed population of HIV viruses. The findings suggest that combination therapies might be essential to prevent HIV in people, highlighting the need for regimens that protect against several targets.
Researchers have found a way to generate long-lasting immune cells that can respond to and stop HIV virus infection. The team demonstrated that a modified gp140 protein approach improves B-cell responses, boosting the ability of B-cells to make protective antibodies against HIV.
A new study reveals how the immune system avoids becoming cancerous by using a hair-trigger protein called Tia1. This protein controls the production of proteins needed to fix damaged DNA, allowing B cells to produce effective antibodies while preventing lasting harm.
Researchers have created antibody-recruiting molecules targeting fungi (ARM-Fs) that can attach to fungal cell walls and recruit human antibodies to combat infections. These small molecules offer a new strategy for treating fungal diseases affecting thousands of people each year.
Researchers at Scripps Research Institute discover a way to reprogram mature skin-like cells into stem cells using antibodies, potentially reducing mutations and improving properties. This method could lead to personalized cell therapies and organ regeneration.
Researchers at Hokkaido University have developed a chimeric anti-PD-L1 antibody that induces immune responses and tumor regression in dogs with malignant cancers. The antibody targets PD-L1-positive cancers, including oral malignant melanoma and undifferentiated sarcoma.
Rice University scientists have developed a method to efficiently modify natural antibodies that can deliver drugs to target cells by adding rhodium, a rare transition metal. The new technique allows labs to test the relative function of various antibody sources and antigen targets to see which will work best on tumor cells.
Research published in Annals of the Rheumatic Diseases found a link between prolonged use of oral contraceptives and reduced risk of developing rheumatoid arthritis. However, breastfeeding was not associated with a significant protective effect after accounting for influential factors.
A new study by Texas Tech University Health Sciences Center El Paso researchers explores the impact of prior West Nile virus exposure on Zika infection. The team collected blood samples from 500 individuals and tested for West Nile antibodies to determine whether previous exposure could inhibit or enhance Zika infection severity.
Scientists have discovered a specific type of immune regulatory cell, T follicular regulatory cells (Tfr), in patients with Sjögren syndrome, an autoimmune disease. Blood Tfr cells are immature and unable to suppress antibody production, but their levels increase in response to flu vaccine exposure.
Researchers at Arizona State University have developed a plant-based Zika vaccine that is more potent, safer and cheaper to produce than existing alternatives. The vaccine targets the DIII domain of the Zika virus and has been shown to induce 100% protection against multiple Zika virus strains in mice.
A new portable platform enables sensitive and rapid diagnostic testing in resource-limited settings, detecting telltale markers of disease as accurately as the most sensitive tests on the market. The D4 assay can identify a disease biomarker in as few as 15 minutes.
A new study found that prior dengue or yellow fever exposure does not increase susceptibility to severe Zika virus infection in rhesus macaques. The researchers observed no significant differences in clinical factors between previously infected and uninfected monkeys after Zika virus infection.
Researchers found that treating patients with IdeS drug before transplantation significantly reduced donor-specific antibodies, allowing successful kidney transplants. The enzyme, produced by Streptococcus pyogenes, can remove organ-rejecting antibodies, making kidney transplantation possible.
Researchers found that prior vaccination in pregnant women did not significantly affect the transfer of flu antibodies to their babies, contradicting initial concerns. Weakened maternal immune responses from repeated flu shots also hindered peak antibody levels.
Researchers have developed a new method to generate specific human antibodies in the laboratory using nanoparticles. This technique can produce high-affinity antibodies within days, offering potential for rapid therapeutic antibody production and accelerated vaccine development.
A team of researchers has successfully manufactured microscopic versions of silkworm cocoons, which can store and protect sensitive molecular materials. The tiny capsules, made from silk nano-fibrils, have the potential to increase the stability and lifetime of antibodies used in pharmaceuticals for treating severe diseases.
A team led by Prof. Arne Skerra has identified an antibody that tightly binds benzopyrene, a widespread environmental toxin linked to cancer. This breakthrough could lead to the development of antibodies to separate aromatic hydrocarbons from contaminated drinking water.
Researchers at TUM have identified an antibody that tightly binds benzo[a]pyrene, a widespread environmental toxin linked to cancer. This breakthrough discovery may lead to the development of antibodies against other PAHs and improved methods to separate contaminants from drinking water.
Tulane University has received a $12 million grant to test a promising drug treatment for Lassa fever and develop a vaccine against the deadly disease. The vaccine targets a recently discovered key antibody target on the surface of the virus, which can block it from infecting host cells.
A recent study by Duke University researchers demonstrates a vaccine approach that appears to protect fetuses from congenital CMV infection. The findings, published in JCI Insight, suggest potent antibodies can prevent viral transmission and severe disease in developing fetuses.
A recent study by the University of Zurich found that exposure to sialic acid from farm animals can prevent asthma in children. This protective effect is due to an anti-inflammatory response triggered by regulatory T-cells, which dampen incorrect immune responses.
Researchers at CNIC reveal CTCF's crucial role in antibody generation and germinal center formation, shedding light on the immune response mechanisms. The study highlights the importance of CTCF for maintaining proper immune function and has implications for vaccine research.
Researchers found that maternal antibodies against HSV-1 can travel to the nervous systems of unborn babies, preventing the development and spread of infection during birth. This protection may help prevent serious brain disease related to these conditions in fetuses and newborns.
Researchers have demonstrated a new therapeutic approach that can re-build and strengthen bone, offering hope for individuals with the debilitating bone cancer, multiple myeloma. The treatment targets a protein called sclerostin, which halts bone formation, and found to double bone volume in some mice.
Researchers at Cornell University discovered a new way to measure tiny amounts of antibodies in foals, helping to understand how quickly they start producing their own. This will aid in optimizing vaccination schedules for young horses.
Researchers at Duke University Medical Center have discovered a new antibody that can restore the effectiveness of chemotherapy rituximab in leukemia patients with natural resistance. The study found that adding the antibody to rituximab increased cancer cell death by 45% in five out of 11 patients.
Researchers develop Affimer technology to replicate antibodies, providing a more robust, smaller, and easier-to-modify alternative. This tool enables scientists to study molecular behavior and reactions with ease, leading to breakthroughs in disease research.
Researchers elucidate mechanisms behind synaptic vesicle motion, finding that type, size of synapse and vesicle composition impact motility. Tracking vesicles reveals active transport to specific destinations, providing clues for neuronal diseases.
Researchers at Université de Genève have developed a new test to detect anti-phospholipid antibody syndrome (APS), an autoimmune disease affecting around 0.5% of the population. The test targets the specific antibody that binds to cells, producing pro-inflammatory and pro-thrombotic factors, offering improved accuracy and standardization.
Researchers developed a 3-D crystal structure of the disease's molecular interactions with a neural receptor, providing a clear view of how it attacks and destroys proteins. The model could accelerate research and lead to new therapies for myasthenia gravis, which affects an estimated 36,000 to 60,000 Americans annually.
Researchers found that Zika viral load and dengue antibodies were not associated with severe symptoms or fetal harm, contradicting previous theories. The study's findings suggest a lack of correlation between the amount of virus in the blood and severity of symptoms in pregnant women.
Scientists at Johns Hopkins created a nanoparticle that carries two different antibodies to simultaneously switch off cancer cells' defensive properties while switching on a robust anticancer immune response in mice. The 'immunoswitch' particles dramatically slowed the growth of mouse melanoma and colon cancer, even eradicating tumors.